In this bonus episode, we’re bringing together seven CEOs across the S2G portfolio to explore what it actually looks like to make food as health a reality within the U.S. healthcare system. In a previous episode, we focused on the obstacles and investor opportunity, so this week we’re steering the conversation to the solutions already being built and tested in the market.

Across clinical nutrition, oncology, care coordination, meal delivery, and life-science AI, leaders from Mend, Big Bold Health, Pyx Health, Mealogic, NourishedRx, Sōlaria Biō, and Brightseed describe how they’re reframing healthcare through food-based solutions. The discussion spans new scientific frameworks for understanding food as a complex, multi-target intervention, the importance of rigorous clinical evidence and FDA pathways, the realities of reimbursement and payer incentives, and the challenge of patient adherence. Woven together, these CEOs create a blueprint for a healthcare system where food-based solutions are preventative, scalable, and central rather than peripheral.

Links:

The Food as Health Opportunity white paper

Big Bold Health

Brightseed

Mealogic

Mend

NourishedRx

Pyx Health

Sōlaria Biō

This content is for informational purposes only, should not be taken as legal, business, tax or investment advice, or be used to evaluate any investment or security, and is not directed at any investor or potential investor in any investment vehicle sponsored by S2G. Investing involves risk, including the risk of loss. Specific companies mentioned in this podcast are for educational purposes and should not be construed as an endorsement of any kind. S2G holds positions in the companies referenced, but this podcast is for information purposes only and is not intended to promote any such company. All views of the guests on this podcast are solely their opinions and do not reflect the opinions of S2G. Any past performance discussed is not indicative of future results. The views expressed herein are opinions based on certain assumptions and subject to change.

For more important information, please see s2ginvestments.com/disclosures.